RxDoctor Payments DataLook up a doctor →

Aqueel Kouser, MD

Rheumatology · Jefferson City, TNNPI 1639129323

Payments from drug & device makers

$13,812in general payments, 2019–2025

Across 774 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Amgen$3K
  • Johnson & Johnson$2K
  • Novartis$1K
  • Pfizer$787
  • AstraZeneca$547
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$13,36897%
  • Education$4433%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,812 in reported general payments places this provider in the 65th percentile of 127 rheumatology providers in Tennessee.

See all rheumatology providers in Tennessee

Medicare billing

Part B allowed, 2024
$129,557
Medicare patients
412
Services billed
3,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab65$471,590
Enbrel SureclickEtanercept44$352,416
Orencia ClickjectAbatacept52$308,325
RinvoqUpadacitinib31$211,503
OtezlaApremilast16$75,517
SimponiGolimumab11$69,909
ProliaDenosumab31$52,986
Hydroxychloroquine Sulfate844$24,124
MethotrexateMethotrexate Sodium334$5,388
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen394$5,343
Pregabalin276$3,754
Diclofenac Sodium331$3,428
Duloxetine Hcl134$3,379
Leflunomide28$2,055
Gabapentin170$1,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$3,733$211,50331 claims
AmgenOtezla, Prolia$2,773$128,50347 claims
Johnson & JohnsonSimponi$1,607$69,90911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 127 rheumatology providers in Tennessee.

Other rheumatology in Jefferson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →